XML 57 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 10, 2018
May 05, 2017
Jul. 31, 2018
May 31, 2017
Mar. 31, 2017
Jan. 31, 2017
Oct. 31, 2016
Apr. 30, 2016
Apr. 28, 2016
May 31, 2015
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
Jun. 11, 2018
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Upfront amount                           $ 297,000      
Amortization of intangible assets                           1,553,705 $ 1,708,771    
Stock issued aggregate shares   6,250                              
Net identifiable asset acquired                                 $ 3,200,000
Net sales                           3,660,120 3,221,590    
Additional paid in capital                           92,681,918 73,069,541    
Third Upfront [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Upfront amount           $ 4,000,000                      
Prostascint Business [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Upfront amount                   $ 1,000,000              
Percentage of a revenue share net sales                   8.00%              
Maximum aggregate payout for sale                   $ 2,500,000              
Contingent consideration valued                   $ 664,000              
Contingent consideration was initially revalued                           0      
Amortization of intangible assets                           61,000 159,000    
Prostascint Business [Member] | Discounted Cash Flow Method [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Contingent consideration was initially revalued                             54,000    
Prostascint Business [Member] | Trade Names [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Amortization of intangible assets                             7,000    
Prostascint Business [Member] | Developed Technology Rights [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Amortization of intangible assets                             54,000    
Prostascint Business [Member] | Customer Contracts [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Amortization of intangible assets                             0    
Jazz Pharmaceuticals Inc [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Share-based payment                     $ 7,400     9,000      
Primsol Business [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Amortization of intangible assets                           0 184,000    
Cash         $ 1,750,000                        
Recognized gain loss         $ 428,000                        
Natesto [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Upfront amount             $ 2,000,000 $ 2,000,000                  
Contingent consideration valued                           1,800,000   $ 3,200,000  
Amortization of intangible assets                           1,300,000 1,300,000    
Recognized gain loss                           $ 0 62,000    
Stock issued aggregate shares                 12,245,411                
Purchase of common stock value                 $ 2,000,000                
Purchase price per share                 $ 0.16                
Maximum aggregate amount payable milestone payments, description                           One-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million.      
Net identifiable asset acquired                           $ 10,500,000      
Contingent consideration accretion expenses                           694,000 228,000    
Natesto [Member] | License and Supply Agreement [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Gross proceeds from the sales                             1,100,000    
Total of cost of sale                             92,000    
Natesto [Member] | License and Supply Agreement [Member] | First Milestone [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
One-time, non-refundable payments                 $ 2,500,000                
Sales revenue target                 25,000,000                
Natesto [Member] | License and Supply Agreement [Member] | Second Milestone [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
One-time, non-refundable payments                 5,000,000                
Sales revenue target                 50,000,000                
Natesto [Member] | License and Supply Agreement [Member] | Third Milestone [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
One-time, non-refundable payments                 7,500,000                
Sales revenue target                 75,000,000                
Natesto [Member] | License and Supply Agreement [Member] | Forth Milestone [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
One-time, non-refundable payments                 10,000,000                
Sales revenue target                 100,000,000                
Natesto [Member] | License and Supply Agreement [Member] | Fifth Milestone [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
One-time, non-refundable payments                 12,500,000                
Sales revenue target                 125,000,000                
Natesto [Member] | CAD [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Purchase of common stock value                 $ 2,500,000                
Purchase price per share                 $ 0.207                
ZolpiMist [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Contingent consideration valued                           3,200,000      
Amortization of intangible assets                           39,000      
Contingent consideration accretion expenses                           $ 23,000 0    
Percentage of net sales, description                           Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020, Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022, Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025.      
Additional paid in capital                                 $ 2,600,000
Nuelle, Inc. [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Maximum aggregate payout for sale       $ 6,900,000                          
Contingent consideration valued       $ 1,900,000                          
Amortization of intangible assets                           $ 110,000 22,000    
Stock issued aggregate shares       6,250                          
Contingent consideration accretion expenses                           $ 64,000 $ 12,000    
Net sales       $ 100,000,000                          
Subsidiaries payment, description       The first $1.0 million of revenue earn-out payments was paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.                          
Revenue earn out payment                         $ 12,000        
Aytu BioScience, Inc. [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Revenue earn out payment                       $ 1,000,000          
Prepayment of common stock issued                       $ 238,000          
Subsequent Event [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Stockholders' equity, reverse stock split, description Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the “Reverse Stock Splits”). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.                                
Subsequent Event [Member] | ZolpiMist [Member]                                  
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                                  
Upfront amount     $ 400,000                            
Additional paid in capital     $ 300,000